Form 990 for tax year 2025

Totals

Total revenue

$321,942,685

Total expenses

$320,553,095

Contributions and grants received

$312,853,222

Grants paid

$73,175,596

Program service revenue

$0

Investment income

$8,107,486

Other revenue

$981,977

Total assets, end of year

$382,170,085

Total liabilities, end of year

$319,141,703

Net assets or fund balances, end of year

$63,028,382

Program services expenses (Part IX)

$290,179,878

Management and general expenses

$28,803,407

Fundraising expenses

$1,569,810

Program service expenses (Part III)

$290,179,878

Program services were 90.5% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2025

• PATH'S PRODUCT DEVELOPMENT DIVISION ENSURES THAT THE RIGHT HEALTH PRODUCTS REACH THE PEOPLE WHO NEED THEMAFFORDABLY AND EFFECTIVELY. WE DEVELOP VACCINES, DIAGNOSTICS, MEDICAL DEVICES, AND DRUG FORMULATIONS FOR LOW-RESOURCE SETTINGS, FROM EARLY-STAGE RESEARCH THROUGH LICENSURE, QUALITY TESTING, AND INTRODUCTION. AS A PRODUCT DEVELOPMENT PARTNERSHIP, WE ACT AS THE GLUECONNECTING PRIVATE-SECTOR MANUFACTURERS, NATIONAL HEALTH PROGRAMS, AND COMMUNITIES. WE ENSURE LIFESAVING HEALTH PRODUCTS ARE DESIGNED FOR REAL-WORLD CONDITIONS SO THEY CAN REACH EVERYONE WHO NEEDS THEM.(CONTINUED ON SCHEDULE O)2025 ACHIEVEMENTS INCLUDE, BUT ARE NOT LIMITED TO:- ADVANCING HPV VACCINE RESEARCHPATH INITIATED A PHASE 3 STUDY TO COMPARE INNOVAX'S NINE-VALENT HUMAN PAPILLOMAVIRUS (HPV) VACCINE WITH GARDASIL 9 USING A SINGLE-DOSE REGIMEN, WITH THE GOAL OF ADDING ANOTHER NINE-VALENT PRODUCT TO THOSE RECOMMENDED FOR USE ON A SINGLE-DOSE SCHEDULE.- TCV INTRODUCTIONSPATH, AS PART OF THE TYPHOID VACCINE ACCELERATION CONSORTIUM, SUPPORTED THREE NATIONAL TYPHOID CONJUGATE VACCINE (TCV) INTRODUCTIONS THAT REACHED 10.5 MILLION IN BURKINA FASO, 21 MILLION IN KENYA, AND 44 MILLION IN BANGLADESH. RESULTS FROM THE PATH-SPONSORED PHASE 3 STUDY OF THE EUBIOLOGICS CO., LTD TCV PRODUCT THAT ENABLED NATIONAL LICENSURE WERE PUBLISHED AND FORMED A CRITICAL PART OF THE DATA PACKAGE FOR WORLD HEALTH ORGANIZATION (WHO) PREQUALIFICATION, WHICH, IF APPROVED, WILL FURTHER INCREASE AVAILABILITY AND ACCESS TO TCV.- EPIDEMIC PREPAREDNESSMANAGED BY PATH, THE RNA COOPERATIVE LAUNCHED IN JUNE 2025 TO STRENGTHEN THREE LOW- AND MIDDLE-INCOME COUNTRY MANUFACTURERS' FOUNDATIONAL RNA VACCINE DEVELOPMENT AND MANUFACTURING CAPACITY. PATH ALSO BECAME THE TECHNICAL COORDINATING PARTNER OF THE RESEARCH PREPAREDNESS PROGRAM IN EAST AND CENTRAL AFRICA TO BOLSTER LOCAL CLINICAL TRIAL CAPACITY AND DISEASE OUTBREAK READINESS. ADDITIONALLY, PATH BEGAN NEWLY FUNDED WORK ON A CORRELATES OF PROTECTION PLAYBOOK TO ACCELERATE THE DEVELOPMENT OF VACCINES AGAINST FILOVIRUSES.- SAFER MALARIA TREATMENT WITH G6PD TESTINGPATH HELPED CO-DEVELOP THE FIRST POINT-OF-CARE TEST FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY TO RECEIVE WHO PREQUALIFICATION. THE STANDARD G6PD TEST USES A SIMPLE FINGER PRICK AND DELIVERS RESULTS IN UNDER TWO MINUTES, PROVIDING A SAFER TREATMENT OF PLASMODIUM VIVAX (P. VIVAX) MALARIA AND REDUCING THE RISK OF DANGEROUS DRUG REACTIONS, ESPECIALLY FOR WOMEN WITH INTERMEDIATE DEFICIENCY LEVELS. IN ETHIOPIA AND VIETNAM, PATH SUPPORTED THE IMPLEMENTATION OF G6PD-TEST-FACILITATED SAFER TREATMENT OF P. VIVAX MALARIA, WITH A NEW SINGLE-DOSE DRUG.- REDUCING HEALTH CARE-ASSOCIATED INFECTIONS A MULTIYEAR COLLABORATION BETWEEN PATH, THE UGANDA MINISTRY OF HEALTH, GHANA HEALTH SERVICE, AND AQUA RESEARCH, LLC RESULTED IN THE FORMAL ADOPTION OF THE AQUA RESEARCH STREAM DISINFECTANT GENERATOR INTO GHANA AND UGANDA'S PUBLIC HEALTH SYSTEMS. THE DEVICE ENABLES STAFF TO GENERATE HIGH-QUALITY CHLORINE ON-SITE WITH THE PUSH OF A BUTTON FOR DISINFECTION AND INFECTION PREVENTION AND CONTROL.

  Expenses $115,137,501 · Grants $35,903,295

• PATH'S GLOBAL HEALTH PROGRAMS DIVISION WORKS IN PARTNERSHIP WITH GOVERNMENTS AND COMMUNITIES TO TURN PROVEN HEALTH INNOVATIONS INTO REAL-WORLD SOLUTIONS THAT REACH THE PEOPLE WHO NEED THEM MOST. WE STRENGTHEN PRIMARY HEALTH CARE SYSTEMS BY EXPANDING ACCESS TO LIFESAVING TOOLS, INCLUDING MALARIA PREVENTIVES AND HIV SERVICES. WE PRIORITIZE BUILDING EVIDENCE, IMPROVING EFFICIENCY, AND SUPPORTING LOCAL HEALTH WORKERS OFTEN USING DIGITAL TOOLS, STRENGTHENED SURVEILLANCE SYSTEMS, AND DATA TO GUIDE SMARTER DECISIONS. WE EQUIP HEALTH SYSTEMS TO PERFORM BETTER, FASTER, AND MORE RELIABLY. OUR GOAL IS INTEGRATED, PERSON-CENTERED CARE THAT SPANS DISEASES AND GEOGRAPHIES, MAKING CARE MORE ACCESSIBLE, EFFECTIVE, AND ALIGNED WITH THE NEEDS OF THE PEOPLE IT SERVES. (CONTINUED ON SCHEDULE O)2025 ACHIEVEMENTS INCLUDE, BUT ARE NOT LIMITED TO:- MALARIA PREVENTION AND SURVEILLANCEPATH'S MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA V) PROVIDED TECHNICAL SUPPORT ACROSS SEVEN COUNTRIES' NATIONAL MALARIA PROGRAMS TO ADVANCE PRIORITIES IN SURVEILLANCE, COMMUNITY CASE MANAGEMENT, DATA USE, AND STRATEGIC PLANNING. THROUGH THE REACHING EVERY AT-RISK COMMUNITY AND HOUSEHOLD WITH MALARIA SERVICES (REACH MALARIA) PROJECT, PATH SUPPORTED SEASONAL PREVENTION CAMPAIGNS THAT REACHED 2.9 MILLION CHILDREN WITH LIFESAVING MEDICINE. THE PROJECT ALSO PARTNERED WITH NATIONAL PROGRAMS IN 22 COUNTRIES TO STRENGTHEN SERVICE DELIVERY AND IMPROVE THE QUALITY OF CARE.AS PART OF THE ROTARY HEALTHY COMMUNITIES CHALLENGE, PATH SUPPORTED INTEGRATED COMMUNITY CASE MANAGEMENT IN NIGERIA AND PROVIDED TECHNICAL ASSISTANCE FOCUSED ON MONITORING AND DATA USE IN THE DEMOCRATIC REPUBLIC OF THE CONGO, MOZAMBIQUE, AND ZAMBIA. - STRENGTHENING PRIMARY HEALTH CAREPATH'S PRIMARY HEALTH CARE PROGRAM STRENGTHENED SUSTAINABLE, PEOPLE-CENTERED, INTEGRATED PRIMARY HEALTH CARE PLATFORMS ACROSS 41 COUNTRIES, REACHING OVER 40 MILLION PEOPLE WITH ESSENTIAL HEALTH CARE. THIS INCLUDES MATERNAL AND CHILDHOOD IMMUNIZATION, WOMEN'S ACCESS TO INJECTABLE CONTRACEPTION, FACILITATION OF HIV AND TUBERCULOSIS (TB) TESTING AND CARE SERVICES, AND ACCESS TO SCREENING, PREVENTION, AND CARE SERVICES FOR NONCOMMUNICABLE DISEASES. - OXYGEN THERAPY AND EQUIPMENT ACCESSTO ADDRESS GAPS IN OXYGEN ACCESS, PATH ESTABLISHED THE OXYGEN DELIVERY GAP FUND TO IDENTIFY AND PROCURE ESSENTIAL CONSUMABLES, ACCESSORIES, AND DEVICES NEEDED TO KEEP OXYGEN FLOWING. THROUGH THIS EFFORT, PATH PROCURED 119,101 PRODUCTS ACROSS FIVE AFRICAN COUNTRIES, ENABLING 790,000 PATIENTS ANNUALLY TO HAVE ACCESS TO OXYGEN DELIVERY SYSTEMS. WORKING IN CLOSE PARTNERSHIP WITH NATIONAL CIVIL SOCIETY AND COMMUNITY ACTORS, PATH LAUNCHED THREE LOCALLY LED ADVOCACY COALITIONS IN KENYA, MALAWI, AND TANZANIA. THESE COALITIONS HELP MOBILIZE LOCAL CHAMPIONS AND CROSS-SECTORAL COLLABORATION TOWARD SUSTAINABLE OXYGEN ECOSYSTEMS.

  Expenses $106,767,987 · Grants $25,799,147

• IN THE ASIA, MIDDLE EAST, AND EUROPE (AMEE) REGION, WE PARTNER WITH COUNTRIES TO TACKLE URGENT HEALTH CHALLENGES AND EXPAND ACCESS TO CARE. WE WORK AT EVERY LEVEL, FROM COMMUNITIES TO NATIONAL GOVERNMENTS, BRINGING SCIENCE, TECHNOLOGY, AND PARTNERSHIPS CLOSER TO WHERE CHANGE HAPPENS. FROM EXPANDING TYPHOID VACCINATION IN BANGLADESH TO IMPROVING HIV SERVICES IN UKRAINE, WE TAILOR OUR SOLUTIONS TO LOCAL NEEDS AND BUILD RESILIENT, SUSTAINABLE HEALTH SYSTEMS. 2025 ACHIEVEMENTS INCLUDE, BUT ARE NOT LIMITED TO:- BANGLADESHPATH SUPPORTED THE DELIVERY AND MONITORING OF TYPHOID VACCINATION CAMPAIGNS TO IMPROVE COVERAGE AND SAVE LIVES. (CONTINUED ON SCHEDULE O)- CAMBODIAPATH CONTINUED WORKING WITH THE GOVERNMENT OF CAMBODIA TO BUILD A SUSTAINABLE ONE HEALTH ARCHITECTURE THAT ENABLES EVIDENCE-BASED DECISION SUPPORT FOR THE PREVENTION, EARLY DETECTION, AND RESPONSE TO INFECTIOUS DISEASES.- CHINAPATH CONTINUED TO ADVANCE THE DEVELOPMENT OF TECHNOLOGIES, INCLUDING DIAGNOSTIC TOOLS FOR TB, HPV, POLIO, AND ROTAVIRUS VACCINES. THE WHO-PREQUALIFIED BIVALENT HPV VACCINE (SUPPORTED BY PATH) WAS INTRODUCED IN CHINA'S NATIONAL IMMUNIZATION PROGRAM.- INDIAPATH ADVANCED MEDICAL OXYGEN SYSTEMS FOR NEWBORN SURVIVAL AND ENGAGED YOUTH FOR IMPROVING TB DIAGNOSIS AND TREATMENT AND GENERATING AWARENESS OF ANTIMICROBIAL RESISTANCE. PATH WORKED TO STRENGTHEN SUPPLY CHAINS FOR IMPROVED ACCESS TO HEALTH PRODUCTS, CREATED DIGITAL HEALTH ROADMAPS, SUPPORTED THE ROLLOUT OF ARTIFICIAL INTELLIGENCEBASED DIAGNOSTIC TOOLS, AND STRENGTHENED INTEGRATED DISEASE SURVEILLANCE OF ACUTE ENCEPHALITIS SYNDROME.- INDONESIAPATH INTRODUCED TOOLS FOR IMPROVING THE CAPACITY OF HEALTH WORKERS TO DELIVER PRIMARY HEALTH CARE AND WORKED WITH THE MINISTRY OF HEALTH TO CONVENE PRIVATE-SECTOR PARTNERS (VACCINES, THERAPEUTICS, AND DIAGNOSTICS) AND STRENGTHEN HEALTH ARCHITECTURE FINANCING AND REGIONAL MANUFACTURING.- MYANMARPATH CONTINUED TO STRENGTHEN TB AND PERINATAL MENTAL HEALTH SERVICES. - PAKISTANPATH SUPPORTED THE CREATION OF A RESULTS FRAMEWORK TO EVALUATE A MULTISECTORAL NUTRITION PROGRAM.- UKRAINEPATH SUPPORTED THE EXPANSION OF NATIONAL E-HEALTH SERVICES AND DELIVERY OF HIV, TB, AND MATERNAL MENTAL HEALTH SERVICES IN WAR-AFFECTED AREAS.- VIETNAMPATH STRENGTHENED ANTIMICROBIAL RESISTANCE SURVEILLANCE, OXYGEN UTILIZATION, AND RESPIRATORY CARE ECOSYSTEMS. PATH ALSO STRENGTHENED ROUTINE IMMUNIZATION SYSTEMS IN SON LA AND IMPROVED WORKPLACE HEALTH AND SAFETY BY IMPROVING WORKER WELL-BEING AND OCCUPATIONAL HEALTH CAPACITY.

  Expenses $33,482,517 · Grants $5,363,501

• AFRICA REGIONIN THE AFRICA REGION, WE PARTNER WITH COUNTRIES TO DELIVER HEALTH PROGRAMS THAT RESPOND TO LOCAL PRIORITIES, FROM MALARIA AND HIV TO VACCINES, EPIDEMIC PREPAREDNESS AND RESPONSE, AND DIGITAL HEALTH AND ARTIFICIAL INTELLIGENCE. WE WORK AT EVERY LEVEL, FROM COMMUNITIES TO NATIONWIDE PROGRAMS, STRENGTHENING EXISTING HEALTH SYSTEMS RATHER THAN CREATING NEW ONES. OUR FOCUS IS ON SUSTAINABILITY AND IMPACT, WHILE OPTIMIZING OPERATIONS AND STAFF SUPPORT. BY COMBINING LOCAL INSIGHT WITH GLOBAL INNOVATION, WE HELP BUILD RESILIENT HEALTH SYSTEMS AND IMPROVE LIVES. 2025 ACHIEVEMENTS INCLUDE, BUT ARE NOT LIMITED TO: - MOZAMBIQUEPATH SUPPORTED THE SCALE-UP OF SELF-INJECTABLE CONTRACEPTIVES ACROSS 143 HEALTH FACILITIES IN SOUTHERN MOZAMBIQUE, REACHING MORE THAN 63,000 CONTRACEPTIVE VISITS AND EXPANDING WOMEN'S ACCESS TO FAMILY PLANNING.- NIGERIAPATH HELPED STRENGTHEN COMMUNITY-BASED HEALTH CARE IN NIGERIA BY TRAINING MORE THAN 700 COMMUNITY HEALTH WORKERS IN 2025 TO EXPAND ACCESS TO EARLY DIAGNOSIS AND TREATMENT.- TANZANIAPATH HELPED IMPLEMENT A BIOMETRIC FINGERPRINT SYSTEM ACROSS APPROXIMATELY 3,600 HEALTH FACILITIES IN TANZANIA, IMPROVING CONTINUITY OF HIV CARE THROUGH SECURE PATIENT IDENTIFICATION. - MULTICOUNTRYPATH SUPPORTED MALARIA VACCINE ROLLOUT ACROSS EIGHT COUNTRIES, HELPING MINISTRIES OF HEALTH PLAN, INTRODUCE, AND DELIVER VACCINES TO MILLIONS OF CHILDREN IN HIGH-BURDEN SETTINGS. PATH SUPPORTED A DIGITAL COLD CHAIN MONITORING SYSTEM BUILT ON THE NATIONAL DHIS2 PLATFORM IN SENEGAL, HELPING ENSURE VACCINES REMAIN SAFE AND EFFECTIVE THROUGH REAL-TIME TEMPERATURE MONITORING. OTHER: ADVOCACY AND PUBLIC POLICYAT PATH'S CENTER FOR ADVOCACY AND PUBLIC POLICY, WE WORK TO ENSURE EVERYONE CAN ACCESS THE HEALTH SERVICES AND INNOVATIONS THEY NEED TO THRIVE. WE PARTNER WITH POLICYMAKERS IN COUNTRIES SUCH AS KENYA, SOUTH AFRICA, AND THE UNITED STATES AND ON THE GLOBAL STAGE TO DRIVE INVESTMENTS AND POLICIES THAT SUPPORT PRIMARY HEALTH CARE, MATERNAL AND CHILD HEALTH, IMMUNIZATION, AND INNOVATION. WE ALSO SUPPORT LOCAL ADVOCACY PARTNERS BY TRANSLATING EVIDENCE INTO CLEAR MESSAGES, BUILDING COALITIONS, AND SHARING KNOWLEDGE. IN 2025, OUR EFFORTS LED TO NEW POLICIES, INCREASED FUNDING, AND STRONGER LOCAL CAPACITY TO SHAPE HEALTH AGENDAS AND IMPROVE HEALTH SYSTEMS AROUND THE WORLD. 2025 ACHIEVEMENTS INCLUDE, BUT ARE NOT LIMITED TO: - EXPANDING ACCESS TO LIFESAVING HEALTH PRODUCTS AND SERVICES IN AFRICAPATH SUPPORTED KENYA TO DEVELOP ITS FIRST LOCAL HEALTH PRODUCTS MANUFACTURING POLICY, A KEY STEP IN ADVANCING REGIONAL SELF-RELIANCE.PATH HELPED DRIVE PROGRESS TOWARD A UNIFIED REGULATORY ENVIRONMENT BY SUPPORTING TWO ADDITIONAL COUNTRIES TO RATIFY THE AFRICAN MEDICINES AGENCY TREATY. IN KENYA, PATH WORKED WITH THE NATIONAL GOVERNMENT TO PILOT A TOOL TO MEASURE THE EFFECTIVENESS OF ITS NEW PRIMARY HEALTH CARE NETWORK SYSTEM. IN NYAMIRA COUNTY, WE SUPPORTED DEVELOPMENT AND ADOPTION OF A LAW TO PROTECT FUNDING FOR HEALTH PRODUCTS AND TECHNOLOGIES. TO ADVANCE MATERNAL, NEWBORN, AND CHILD HEALTH AND IMMUNIZATION IN AFRICA, PATH LED CO-CREATION EFFORTS WITH KEY REGIONAL AND GLOBAL PARTNERS, RESULTING IN UNIFIED ADVOCACY STRATEGIES TO GUIDE PARTNER EFFORTS.

  Expenses $34,791,873 · Grants $6,109,653

As filed on the 2025 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

• CLINTON HEALTH ACCESS INITIATIVE

  $1,772,283

  AFRICA, GLOBAL HEALTH PROGRAMS

• NEW YORK UNIVERSITY DBA NYU GROSSMAN SCHOOL OF MEDICINE

  $1,769,405

  PRODUCT DEVELOPMENT

• JHPIEGO

  $1,244,119

  AFRICA, AMEE, GLOBAL HEALTH PROGRAMS

• JSI RESEARCH AND TRAINING INSTITUTE INC

  $1,135,026

  GLOBAL HEALTH PROGRAMS

• UNIVERSITY OF WASHINGTON ( UW )

  $1,097,310

  GLOBAL HEALTH PROGRAMS, PRODUCT DEVELOPMENT

• HJF MEDICAL RESEARCH INTERNATIONAL INC

  $981,270

  PRODUCT DEVELOPMENT

• OPENMRS INC

  $742,446

  GLOBAL HEALTH PROGRAMS

• POPULATION SERVICES INTERNATIONAL INC

  $457,027

  GLOBAL HEALTH PROGRAMS

• NATIONAL FOUNDATION FOR THE CDC

  $296,623

  PRODUCT DEVELOPMENT

• TULANE UNIVERSITY

  $291,939

  GLOBAL HEALTH PROGRAMS, PRODUCT DEVELOPMENT

The 10 largest by cash amount. The API serves every itemized grant.

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

• FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND

  501(C)(3) · EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH · SZ · controlled entity

  Directly controlled by PATH

• PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH -KENYA

  501(C)(3) · EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH · KE · controlled entity

  Directly controlled by PATH

• ORGANIZATION FOR INNOVATION IN PUBLIC HEALTH LTD BY GUARANTEE - NIGERIA

  501(C)(3) · EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH · NI · controlled entity

  Directly controlled by PATH

Provenance

Return type

form_990

Tax year

2025

Filed

17 September 2026

IRS schema version

2025v4.2

Source object

202622609349301302

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.